We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
- Biochemistry
-
1. De novo designed proteins: a breakthrough in snakebite treatment
- Dr. Susana Vazquez Torres
- Cancer/Oncology
-
3. From lab to clinic: bridging cancer genetics and public health
- Prof. Clare Turnbull
-
4. Engineered yeast: a breakthrough in targeted cancer therapies
- Prof. Gautam Dantas
-
6. Cancer vaccines
- Dr. Elias Sayour
-
7. The future of blood tests in cancer treatment
- Dr. Isaac Garcia-Murillas
-
9. Artificial intelligence in precision medicine
- Dr. Michael P. Menden
-
10. How liver X receptor regulates intestinal regeneration and tumor growth
- Dr. Srustidhar Das
- Immunology & Inflammation
-
11. Role of ETS2 in autoimmune and inflammatory diseases
- Dr. James Lee
-
12. Rheumatic diseases and musculoskeletal pain
- Prof. Anisur Rahman
-
14. Transmembrane domains and the regulation of trogocytosis in T cells
- Dr. Stefano Barbera
- Infectious Diseases/Microbiology
-
16. Kalihinol analog MED6-189: a promising pan-antimalarial candidate
- Prof. Karine Le Roch
-
17. Elite controllers of HIV: from discovery to future therapies
- Prof. Bruce Walker
-
19. Towards developing a universal influenza vaccine
- Prof. Peter Palese
- Methods
-
21. How big data and genomics are personalizing your health- Prof. Michael Snyder
-
22. The role of preregistration and registered reports in improving research transparency and reproducibility
- Dr. Peter Bonde Ernst-Rasmussen
-
23. Decoding aging: how a proteomic clock predicts mortality and disease across populations
- Dr. M. Austin Argentieri
-
24. MassBank development and future
- Dr. Emma L. Schymanski
-
25. Synthetic whole embryo models and their applications
- Prof. Jacob (Yaqub) Hanna
-
26. Pioneering proteomics: insights on advancements in the science of proteins
- Prof. Ruedi Aebersold
- Neurology/Neuroscience
-
27. Duchenne muscular dystrophy: pathology, diagnostic strategies, and core molecular pathways- Prof. Steve Wilton
-
28. Rethinking the amyloid dogma in Alzheimer’s disease
- Prof. George Perry
-
29. Integrated multimodal cell atlas of Alzheimer’s disease
- Dr. Michael Hawrylycz
-
30. How and why neurons die in Alzheimer's disease?
- Prof. Bart De Strooper
-
31. Restoring glucose metabolism: a new approach to reversing cognitive decline in AD
- Prof. Katrin Andreasson
-
32. Advancing ALS genetics through accessible testing
- Dr. Teresa Fecteau
-
33. MicroRNA as a biomarker for early detection of amyotrophic lateral sclerosis
- Dr. Sandra Banack
- Dr. Paul Alan Cox
- Dr. Rachael Dunlop
-
34. Translational research in amyotrophic lateral sclerosis (ALS)
- Prof. Aaron D. Gitler
-
35. Muscarinic acetylcholine receptor modulation in neurological diseases
- Prof. Andrew B. Tobin
- Pharmaceutical Sciences
-
36. The state of the art in secondary pharmacology
- Dr. Jean-Pierre Valentin
-
37. The safety, toxicology, and regulation of antibody-drug conjugates
- Dr. Veysel Kayser
-
39. Management of generic drug development: challenges and opportunities
- Mr. Sandeep Patil
-
40. Translational medicine: the risk of failure in delay and how to reduce it
- Prof. Martin Wehling
-
41. Artificial intelligence in guiding cancer treatment decisions
- Prof. Eytan Ruppin
-
42. The regulation of cell therapy
- Prof. Moutih Rafei
-
43. Scale-up challenges in the production of nanomedicines from lab to industry
- Prof. Dr. Oya Tagit
-
44. Challenges and solutions of scaling up
- Dr. Shaukat Ali
-
46. Using real-world insights on drug interactions to inform drug development
- Dr. Amita Datta-Mannan
-
47. Role of marketing authorization holder in drug safety
- Dr. Raphael Elmadjian Pareschi
Topics Covered
- What is Precision Cancer Medicine?
- What is required for accurate PCM technology?
- How to create a PCM system to help the whole population
- The use of PCM technology to support patient and family treatment decision making
- Combating patient variability in PCM
Biography
A nationally-renowned oncologist, Dr. Markman is President of Medicine and Science at Cancer Treatment Centers of America (CTCA).
Dr. Markman has more than 30 years of experience in cancer treatment and research at some of the country’s most recognized facilities, with a particular focus on new drug development and exploring novel management strategies in the area of female pelvic cancers. Dr. Markman has been the primary author or co-author on over 1,500 published peer-reviewed manuscripts, reviews, book chapters, editorials or abstracts, and has written, edited or co-edited 24 books on various topics in the management of malignant disease.
He is widely regarded for his knowledge and expertise as a practicing clinical oncologist and is frequently asked to be a visiting professor and guest lecturer at universities and medical schools across the country. He has served as a member of numerous national and regional oncology committees.
Talk Citation
Markman, M. (2020, April 14). Precision cancer medicine: development and future [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved June 8, 2026, from https://doi.org/10.69645/IGUJ7746.Export Citation (RIS)
Publication History
- Published on April 14, 2020
Financial Disclosures
- Prof. Maurie Markman has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.